First Time Loading...

Yield10 Bioscience Inc
NASDAQ:YTEN

Watchlist Manager
Yield10 Bioscience Inc Logo
Yield10 Bioscience Inc
NASDAQ:YTEN
Watchlist
Price: 0.2899 USD 2.8%
Updated: Apr 16, 2024

ROE
Return on Equity

-1 508.1%
Current
-261%
Average
-29.2%
Industry
Negative for the last year
-1 508.1%
Negative average
-261%
Worse than average
Worse than industry value

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-1 508.1%
=
Net Income
-14.5m
/
Equity
-691.5k

ROE Across Competitors

ROE Comparison
Yield10 Bioscience Inc Competitors

Country Company Market Cap ROE
US
Yield10 Bioscience Inc
NASDAQ:YTEN
4.5m USD
-1 508%
US
Abbvie Inc
NYSE:ABBV
288.2B USD
35%
US
Amgen Inc
NASDAQ:AMGN
142B USD
136%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
23%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
98B USD
16%
AU
CSL Ltd
ASX:CSL
132.7B AUD
15%
US
Gilead Sciences Inc
NASDAQ:GILD
84.2B USD
26%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
US
Moderna Inc
NASDAQ:MRNA
40.2B USD
-29%
US
Biogen Inc
NASDAQ:BIIB
28.5B USD
8%
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD
9%
Yield10 Bioscience Inc
NASDAQ:YTEN
Country US
Market Cap 4.5m USD
ROE
-1 508%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 288.2B USD
ROE
35%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 142B USD
ROE
136%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 102.4B USD
ROE
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 98B USD
ROE
16%
CSL Ltd
ASX:CSL
Country AU
Market Cap 132.7B AUD
ROE
15%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 84.2B USD
ROE
26%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
ROE
-28%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 40.2B USD
ROE
-29%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 28.5B USD
ROE
8%
Horizon Therapeutics PLC
NASDAQ:HZNP
Country IE
Market Cap 26.6B USD
ROE
9%

Profitability Report

View the profitability report to see the full profitability analysis for Yield10 Bioscience Inc.

Full Profitability Report

See Also

Summary
YTEN intrinsic value, competitors valuation, and company profile.
DCF Valuation
YTEN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
YTEN stock valuation using valuation multiples.
Wall Street Estimates
YTEN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
YTEN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Return on Equity?

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-1 508.1%
=
Net Income
-14.5m
/
Equity
-691.5k
What is the ROE of Yield10 Bioscience Inc?

Based on Yield10 Bioscience Inc's most recent financial statements, the company has ROE of -1 508.1%.

ALPHA SPREAD
Join more than 128,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.